Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial.

ABSTRACT: We characterized population pharmacokinetics in 42 African children receiving once-daily 25 mg (14 to <20 kg) or 50 mg (>20 kg) dolutegravir. Coadministration with emtricitabine and tenofovir alafenamide reduced dolutegravir bioavailability by 19.6% (95% confidence interval: 8.13%-30.8%) compared with zidovudine or abacavir with lamivudine. Nevertheless, concentrations remained above efficacy targets, confirming current dosing recommendations.

SUBMITTER: Waalewijn H 

PROVIDER: S-EPMC11424990 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature